| Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma CM Annunziata, RE Davis, Y Demchenko, W Bellamy, A Gabrea, F Zhan, ... Cancer cell 12 (2), 115-130, 2007 | 1146 | 2007 |
| Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity NS Azad, EM Posadas, VE Kwitkowski, SM Steinberg, L Jain, ... Journal of Clinical Oncology 26 (22), 3709-3714, 2008 | 382 | 2008 |
| Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial ML Disis, MH Taylor, K Kelly, JT Beck, M Gordon, KM Moore, MR Patel, ... JAMA oncology 5 (3), 393-401, 2019 | 356 | 2019 |
| Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline PA Konstantinopoulos, B Norquist, C Lacchetti, D Armstrong, RN Grisham, ... Journal of Clinical Oncology 38 (11), 1222-1245, 2020 | 323 | 2020 |
| Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial … JM Lee, A Cimino-Mathews, CJ Peer, A Zimmer, S Lipkowitz, ... Journal of Clinical Oncology 35 (19), 2193-2202, 2017 | 253 | 2017 |
| Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression CM Rice, LC Davies, JJ Subleski, N Maio, M Gonzalez-Cotto, C Andrews, ... Nature communications 9 (1), 5099, 2018 | 249 | 2018 |
| Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses JM Lee, JL Hays, CM Annunziata, AM Noonan, L Minasian, JA Zujewski, ... Journal of the National Cancer Institute 106 (6), dju089, 2014 | 224 | 2014 |
| Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors JM Weiss, LC Davies, M Karwan, L Ileva, MK Ozaki, RYS Cheng, ... The Journal of clinical investigation 128 (9), 3794-3805, 2018 | 190 | 2018 |
| Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer CM Annunziata, HT Stavnes, L Kleinberg, A Berner, LF Hernandez, ... Cancer 116 (13), 3276-3284, 2010 | 186 | 2010 |
| Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study JM Lee, J Nair, A Zimmer, S Lipkowitz, CM Annunziata, MJ Merino, ... The Lancet Oncology 19 (2), 207-215, 2018 | 185 | 2018 |
| Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline J Chino, CM Annunziata, S Beriwal, L Bradfield, BA Erickson, EC Fields, ... Practical radiation oncology 10 (4), 220-234, 2020 | 166 | 2020 |
| Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, ... Clinical Cancer Research 26 (16), 4268-4279, 2020 | 162 | 2020 |
| Activation of NF-κB signaling by inhibitor of NF-κB kinase β increases aggressiveness of ovarian cancer L Hernandez, SC Hsu, B Davidson, MJ Birrer, EC Kohn, CM Annunziata Cancer research 70 (10), 4005-4014, 2010 | 145 | 2010 |
| Reed-Sternberg cell genome expression supports a B-cell lineage J Cossman, CM Annunziata, S Barash, L Staudt, P Dillon, WW He, ... Blood, The Journal of the American Society of Hematology 94 (2), 411-416, 1999 | 131 | 1999 |
| The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome JJ Driscoll, D Pelluru, K Lefkimmiatis, M Fulciniti, RH Prabhala, PR Greipp, ... Blood, The Journal of the American Society of Hematology 115 (14), 2827-2834, 2010 | 128 | 2010 |
| Rapid image deconvolution and multiview fusion for optical microscopy M Guo, Y Li, Y Su, T Lambert, DD Nogare, MW Moyle, LH Duncan, ... Nature biotechnology 38 (11), 1337-1346, 2020 | 123 | 2020 |
| Proteasome inhibitors: structure and function AT Nunes, CM Annunziata Seminars in oncology 44 (6), 377-380, 2017 | 123 | 2017 |
| Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular … MS Poruchynsky, DL Sackett, RW Robey, Y Ward, C Annunziata, T Fojo Cell Cycle 7 (7), 940-949, 2008 | 120 | 2008 |
| Characterization of ovarian cancer cell lines as in vivo models for preclinical studies L Hernandez, MK Kim, LT Lyle, KP Bunch, CD House, F Ning, ... Gynecologic oncology 142 (2), 332-340, 2016 | 114 | 2016 |
| Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer CM Annunziata, J O'Shaughnessy Clinical Cancer Research 16 (18), 4517-4526, 2010 | 114 | 2010 |
